Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 3Phase 1/2 3Phase 1 2

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Dermatologic 1

Conditions

Breast Neoplasms 298Carcinoma, Non-Small-Cell Lung 225Neoplasms 155Prostatic Neoplasms 154Multiple Myeloma 116Neoplasm Metastasis 83Colorectal Neoplasms 80Leukemia, Myeloid, Acute 74Lung Neoplasms 71Parkinson Disease 4, Autosomal Dominant Lewy Body 68Melanoma 67Leukemia, Lymphocytic, Chronic, B-Cell 63Lymphoma, Follicular 62Lymphoma, Non-Hodgkin 61Papillomavirus Infections 59Leukemia 59Pain 52Lymphoma 52Uterine Cervical Neoplasms 50Precursor Cell Lymphoblastic Leukemia-Lymphoma 49Ovarian Neoplasms 47Carcinoma, Hepatocellular 46Keratosis, Actinic 44Carcinoma, Renal Cell 44Recurrence 43Head and Neck Neoplasms 43Stomach Neoplasms 38Lymphoma, Large B-Cell, Diffuse 34Urinary Bladder Neoplasms 33Squamous Cell Carcinoma of Head and Neck 32

Interventions

Ipilimumab 2tremelimumab 1tilsotolimod 1pembrolizumab 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Has results × Diabetes Mellitus, Insulin-Dependent, 12 × Clear all
NCT03302234 2023-09-26

KEYNOTE-598

Merck Sharp & Dohme LLC

Phase 3 Completed
568 enrolled 20 charts
Thoracic

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03084471 2022-12-22

STRONG

AstraZeneca

Phase 3 Completed
867 enrolled 10 charts

Diabetes Mellitus, Insulin-Dependent, 12

NCT03445533 2022-11-08

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

Idera Pharmaceuticals, Inc.

Phase 3 Terminated
481 enrolled 22 charts
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasm Metastasis, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡